Renin, prorenin, and renin gene expression in rats with acute nephrotic syndrome

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 6, 1997, Pages 408-414

  Ibarra Rubio, María Elena ^a,b   Ramos V , Margarita ^a   Correa Rotter, Ricardo ^a   Pedraza Chaverrí, José ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

nephrotic syndrome; prorenin; renin; renin gene expression; renin mRNA

Indexed keywords

PRORENIN; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE EXPRESSION REGULATION; MALE; NEPHROTIC SYNDROME; NONHUMAN; PLASMA RENIN ACTIVITY; PROTEIN DETERMINATION; PROTEIN PROCESSING; RAT; RENIN RELEASE; TRANSLATION REGULATION;

EID: 0031007361     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01210.x     Document Type: Article

References (64)

1. Pedraza-Chaverrí J, Cruz C, Ibarra-Rubio ME et al. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia and renin-angiotensin-aldosterone system on the sodium retention. Rev. Invest. Clin. 1990; 42: 29-38.
2. Glassock RJ, Cohen AH, Adler SG. Primary glomerular diseases. In: Brenner BM (ed.). The Kidney, 5th edn. WB Saunders Co., Philadelphia. 1996; Ch. 30.
3. Pyo HJ, Summer SN, Niederberger M, Kim JK, Schrier RW. Arginine-vasopressin gene expression in rats with puromycin-induced nephrotic syndrome. Am. J. Kidney Dis. 1995; 25: 58-62.
4. Ricardo SD, Bertram JF, Ryan GB. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol. Exp. Nephrol. 1995; 3: 270-9.
5. Bernard DB. Metabolic abnormalities in nephrotic syndrome: Pathophysiology and complications. In: Stein JH (ed.). Contemporary Issues in Nephrology. Churchill Livingstone, New York. 1982; Ch. 4.
6. Yayama K, Konishi K, Ohta A et al. Elevation of plasma angiotensinogen in rats with experimentally induced nephrosis. Nephron 1993; 63: 89-93.
7. Pedraza-Chaverrí J, Cruz C, Ibarra-Rubio ME, Hernández C, Tapia E, Peña JC. Urinary excretion of renin and angiotensinogen in nephrotic rats. Nephron 1991; 57: 106-8.
8. Arévalo AE, Ibarra-Rubio ME, Cruz C, Peña JC, Pedraza-Chaverrí J. Angiotensin I converting enzyme activity in puromycin aminonucleoside-nephrotic syndrome. Clin. Chim. Acta 1990; 191: 175-84.
9. Morris BJ, Smith DL. Prorenin and gene activation. Can. J. Physiol. Pharmacol. 1991; 69: 1367-74.
10. Hollenberg NK, Ingelfinger JR, Dzau VJ. The renin angiotensin system. In: Narins RG (ed.). Clinical Disorders of Fluid and Electrolyte Metabolism, 5th edn. McGraw-Hill Inc., New York. 1994; Ch. 16.
11. Morris BJ. New possibilities for intracellular renin and inactive renin now that the structure of the human renin gene has been elucidated. Clin. Sci. 1986; 71: 345-55.
12. Catanzaro DF, Mullins JJ, Morris BJ. The biosynthetic pathway of renin. J. Biol. Chem. 1983; 258: 7364-8.
13. Sealey JE, von Lutterotti N, Rubattu S et al. The greater renin system. Its prorenin-directed vasodilator limb: Relevance to diabetes mellitus, pregnancy, and hypertension. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn. Raven Press Ltd, New York. 1995; Ch. 111.
14. Nielsen AH, Poulsen K. Is prorenin of physiological and clinical significance? J. Hypertens. 1988; 6: 949-58.
15. Hsueh WA, Baxter JD. Human prorenin. Hypertension 1991; 17: 469-79.
16. Derkx FHM, Schalekamp MADH. Human prorenin: Pathophysiology and clinical implications. Clin. Exp. Hypertens. 1988; A10: 1213-25.
17. Toffelmire EB, Slater K, Corvol P, Menard J, Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. J. Clin. Invest. 1989; 83: 679-87.
18. Barrett JD, Eggena P. The influence of acute stress on active and inactive renin in the rat. Clin. Exp. Hypertens. 1986; A8: 1171-8.
19. Barrett JD, Eggena P, Sambhi MP. In vivo and in vitro alterations of active and inactive plasma renins in the rat. Hypertension 1982; 4 (Suppl. I): I175-9.
20. Jindra A Jr, Kvetnansky R. Stress-induced activation of inactive renin. Molecular weight aspects. J. Biol. Chem. 1982; 257: 5997-9.
21. Hare GMT, Ioannous P, Dubiski S, Osmond DH. Regulated systemic activation of rat plasma prorenin. Hypertension 1987; 10: 122-6.
22. Nakamura N, Soubrier F, Menard J, Panthier JJ, Rougeon F, Corvol P. Nonproportional changes in plasma renin concentration, renal renin content, and rat renin messenger RNA. Hypertension 1985; 7: 855-9.
23. Moffet RB, McGowan RA, Gross KW. Modulation of kidney renin messenger RNA levels during experimentally induced hypertension. Hypertension 1986; 8: 874-82.
24. Barrett GL, Morgan TO, Smith M, Alcorn D, Aldred P. Effect of converting enzyme inhibition on renin synthesis and secretion in mice. Hypertension 1989; 14: 385-95.
25. Correa-Rotter R, Hostetter TH, Rosenberg ME. Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int. 1992; 41: 796-804.
26. Ibarra-Rubio ME, Pedraza-Chaverrí J. El concepto actual del sistema renina-angiotensina. Rev. Invest. Clin. 1993; 45: 165-77.
27. Ekker M, Tronik D, Rougeon F. Extrarenal transcription of the renin genes in multiple tissues of mice and rats. Proc. Natl Acad. Sci. USA 1989; 86: 5155-8.
28. Lou Y, Smith L, Robinson BO, Morris BJ. Renin gene expression in various tissues determined by single-step polymerase chain reaction. Clin. Exp. Pharmacol. Physiol. 1991; 18: 357-62.
29. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin angiotensin system. Am. J. Physiol. 1988; 255: F563-73.
30. Suzuki F, Lindpaintner K, Keuneke C et al. Tissue-specific regulation of gene expression for renin and angiotensinogen. Clin. Exp. Hypertens. 1988; A10: 1317-19.
31. Lou Y, Liu DT, Whitworth JA, Morris BJ. Renin mRNA, quantified by polymerase chain reaction, in renal hypertensive rat tissues. Hypertension 1995; 26: 656-64.
32. Morris BJ. Some physiological outcomes of renin gene studies. Clin. Exp. Pharmacol. Physiol. 1995; 22: 966-75.
33. Schunkert H, Ingelfinger JR, Dzau VJ. Evolving concepts of the intrarcnal renin-angiotensin system in health and disease: Contributions of molecular biology. Renal Physiol. Biochem. 1991; 14: 146-54.
34. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77 (Suppl. I): 14-13.
35. Campbell DJ. Circulating and tissue angiotensin system. J. Clin. Invest. 1987; 79: 1-6.
36. Ibarra-Rubio ME, Pedraxa-Chaverrí J, Panduro A. Differential regulation in the expression of hepatic genes in nephrotic and pair-fed rats. Nephron 1993; 65: 119-24.
37. Thabet MA, Challa A, Chan W, Liu F, Hintz RL, Chan JCM. Insulin-like growth factor and growth hormone receptor in nephrotic rats. Am. J. Physiol. 1994; 266: E102-6.
38. Iwao H, Fukui K, Kim S et al. Sodium balance effects on renin, angiotensinogen, and atrial natriuretic polypeptide mRNA levels. Am. J. Physiol. 1988; 255: E129-36.
39. Rosenberg ME, Chimielewski D, Hostetter TH. Effect of dietary protein on rat renin and angiotensinogen gene expression. J. Clin. Invest. 1990; 85: 1144-9.
40. Pedraza-Chaverrí J, Cruz C, Chávez MT, López A, Ibarra-Rubio ME, Tapia E, Peña JC. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. II. In vitro release of renin, angiotensinogen and aldosterone. Rev. Invest. Clin. 1990; 42: 120-6.
41. Pedraza-Chaverrí J, Zúñiga-Estrada A, Ibarra-Rubio ME, Cruz C, Tapia E, Peña JC. Producción de anticuerpos policlonales para la cuantificación del decapéptido angiotensina 1 per radioinmunoanálisis. Rev. Invest. Clin. 1988; 40: 365-77.
42. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
43. Burnham CHE, Hawelu-Johnson CL, Frank BM, Lynch KR. Molecular cloning of rat renin cDNA and its gene. Proc. Natl Acad. Sci. USA 1987; 84: 5605-9.
44. Baker BR, Joseph JP, Williams JH. Puromycin. Synthetic studies. VII. Partial synthesis of aminoacid analogs. J. Am. Chem. Soc. 1954; 76: 2838.
45. Nathans D, Neidle A. Structural requirements for puromycin inhibition of protein synthesis. Nature 1963; 197: 1076-7.
46. Chow SC, Peters I, Orrenius S. Reevaluation of the role of de novo protein synthesis in rat thymocyte apoptosis. Exp. Cell Res. 1995; 216: 149-59.
47. Lewandowski AE, Liao WSL, Stinson-Fisher CA, Kent JD, Jefferson LS. Effects of experimentally induced nephrosis on protein synthesis in rat liver. Am. J. Physiol. 1988; 254: C634-42.
48. Barrett JD, Eggena P. Trypsin activation of inactive renin: Plasma blanks and angiotensin 1 radioimmunoassay. Can. J. Physiol. Pharmacol. 1991; 69: 1315-20.
49. Barrett JD, Eggena P. Effects of trypsin on the measurement of inactive renin in rat plasma by radio-immunoassay: Decrease in inactive renin following nephrectomy. J. Hypertens. 1988; 6: 49-55.
50. Osmond DH, Sealey JE, McKenzie JK. Activation and function of prorenin: Different viewpoints. Can. J. Physiol. Pharmacol. 1991; 69: 1308-14.
51. Poulsen K, Nielsen AH, Johannessen A. Measurement of inactive renin in normal, nephrectomized, and adrenalectomized rats. Can. J. Physiol. Pharmacol. 1991; 69: 1381-4.
52. Ioannou P, Loh AY, Osmond DH. Activation and measurement of plasma prorenin in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1331-10.
53. Johannessen A, Nielsen AH, Poulsen K. Measurement of inactive renin in rat plasma: Effect of nephrectomy and sialoadenectomy on the plasma concentration. J. Hypertens. 1990; 8: 345-9.
54. Jindra A Jr, Bultas J, Ort J. Investigation of human and rat inactive renin in plasma and kidney. Can. J. Physiol. Pharmacol. 1991; 69: 1341-9.
55. Hsueh WA, Do YS, Wang PH. Observations on the renal processing and sorting of prorenin. Can. J. Physiol. Pharmacol. 1991; 69: 1327-30.
56. King JA, Lush DJ, Fray JCS. Regulation of renin processing and secretion: Chemiosmotic control and novel secretory pathway. Am. J. Physiol. 1993; 265: C305-20.
57. Luetscher JA, Kramer FB, Wilson DM. Prorenin and vascular complication of diabetes. Am. J. Hypertens. 1989; 2: 382-6.
58. Lush DJ, King JA, Fray JCS. Pathophysiology of low renin syndromes: Sites of renal renin secretory impairment and prorenin overexpression. Kidney Int. 1993; 43: 983-99.
59. Gómez RA, Lynch KR, Chevalier RL et al. Renin and angiotensinogen gene expression and intrarenal renin distribution during ACE inhibition. Am. J. Physiol. 1988; 254: F900-6.
60. Nielsen AH, Poulsen K. Evidence for a predominant renal secretion and clearance of inactive plasma renin, studied by in vitro inhibition of protein synthesis. J. Hypertens. 1989; 2: 382-6.
61. Marks DL, Kost LJ, Kuntz SM, Romero JC, LaRusso NF. Hepatic processing of recombinant human renin: Mechanisms of uptake and degradation. Am. J. Physiol. 1991; 261: G349-58.
62. Opsahl JA, Goldberg MR, Katz SA. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Am. J. Hypertens. 1995; 8: 1090-8.
63. Campbell WG Jr, Catanzaro DF, Gahnem F, Sealey JE. Prorenin better reflects renal renin mRNA than renin. J. Hypertens. 1996; 14: S211.
64. Kim S, Hosoi M, Ikemoto F, Murakami K, Ishizuka Y, Yamamoto K. Conversion to renin of exogenously administered recombinant human prorenin in liver and kidney of monkeys. Am. J. Physiol. 1990; 258: E451-8.